Syndax Pharmaceuticals SNDX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$42.67M+37.3% | -$68.01M-12.0% | -$60.72M+15.5% | -$71.85M+15.3% | -$84.85M+9.9% | ||
| $12.05M+7.1% | $11.25M-6.9% | $12.08M-12.4% | $13.79M+32.8% | $10.38M-15.6% | ||
| -$50.35M+27.5% | -$69.49M+1.5% | -$70.54M+19.7% | -$87.8M+7.7% | -$95.16M-65.8% | ||
| $38.39M-52.9% | $81.58M+12.6% | $72.43M+72.9% | $41.89M-55.5% | $94.14M+135% | ||
| $7.92M+33.8% | $5.92M-5.8% | $6.28M+1,039% | $551K-40.8% | $930K-99.7% | ||
| -$4.04M— | —— | —— | -$45.36M-50,297% | -$90K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Syndax Pharmaceuticals generate?
- Syndax Pharmaceuticals (SNDX) generated -$278.2M in operating cash flow over the trailing twelve months.
- Where does Syndax Pharmaceuticals's cash flow data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
